Fundraising Fox
OUP (Osage University Partners)
Venture capitalBala Cynwyd · Pre-Seed–Late Stage · 21 people tracked
Also known as Osage University Partners · OUP MANAGEMENT CO., LLC
Find your way into OUP (Osage University Partners)
Sign up to see every warm intro you have to OUP (Osage University Partners)
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OUP (Osage University Partners) team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
OUP backs science-driven startups that commercialize transformational deep technology innovations emerging from or inspired by breakthrough research. With over 15 years of singular focus on research-originated companies, the firm positions itself as a preferred partner for entrepreneurs, scientists, and students. Its team of former scientists, strategy consultants, and operators brings domain expertise in deep technologies, having backed more than 150 startups. OUP helps founders transition laboratory discoveries to market-ready businesses, navigating university entrepreneurial ecosystems and technology transfer offices. The firm reserves meaningful capital for follow-on rounds, connects companies to Fortune 500 leaders and strategic partners, and works alongside founders to turn technology into winning products.
Source: firm website, verified Oct 17, 2026.
Team · 21 people
from the firm's website & public directories
Anna Turetsky joined OUP in 2025 as General Partner of the $50M PxB Fund (Penn-BioNTech Innovative Therapeutics Seed Fund), focusing exclusively on life science companies emerging from University of Pennsylvania technologies. She previously launched and led the venture investing arm of the Mark Foundation for Cancer Research and began her career at Lightstone Ventures. She holds a Ph.D. in Biophysics from Harvard University and a B.A. in Biochemistry from the University of Pennsylvania.
Louis Berneman heads Texelerate, LLC, a technology transfer consultancy specializing in startup investment, royalty monetization, and licensing transactions. He is founding partner emeritus of Osage University Partners and fund advisor emeritus to HealthCare Royalty Partners, with prior experience as managing director of the Center for Technology Transfer at the University of Pennsylvania. Over 30 years, he has worked in intellectual property licensing, business development, and entrepreneurial activities, and holds certifications as a Licensing Professional and Registered Technology Transfer Professional.
Kirsten Leute has 19 years of experience in technology transfer, including roles at Stanford University and the German Cancer Research Center. Before joining OUP, she served as Associate Director at Stanford's Office of Technology Licensing, where she managed portfolios of inventions across many technology areas with a concentration in biotechnology. She is a former two-time board member of the Association of University Technology Managers and co-founded Equalize Startups, a nonprofit supporting women-led startups.
Bill Harrington joined OUP in 2012 and, as a Managing Partner, oversees the firm's life science investment activities and shares day-to-day execution responsibilities. He previously spent over a decade as a General Partner at Three Arch Partners investing in therapeutics, medical devices, and healthcare services, and earlier practiced as an interventional radiologist. He holds a BS from Tufts, an MD from Harvard Medical School, an MBA from UC Berkeley, and the CFA designation.
Manny Stockman is Managing Partner at Osage University Partners, a venture capital fund that invests in technology spinouts from partner universities across the US, Canada, Israel, and the UK. His investment portfolio spans deep technology across computing, sensing, materials, and software sectors, including companies such as SiFive, IonQ, NuMat, Censys, and Delfi Diagnostics.
Managing Partner on the technology side of OUP's investment team, offering perspectives on diligencing VCs, round syndication, and term-sheet red flags.
Matt Cohen is Managing Partner at Osage University Partners, a venture capital firm investing in innovative technologies derived from university research. He previously worked as a management consultant on projects spanning growth strategy, portfolio prioritization, commercialization planning, and commercial due diligence across multiple industries. Cohen has extensive knowledge of vaccine, immunologic, biologic, and small molecule therapeutic approaches in U.S., European, Brazilian, and Asian markets, with investments in numerous biotechnology companies including PMV Pharmaceuticals, Kura Oncology, Biohaven Pharma, Beam Therapeutics, and Sana Biotechnology.
Robert Adelson runs complementary early-stage B2B SaaS and university-spinout funds, combining corporate law and 1990s buyout experience with long-tenure VC insight and a 50-year university-ecosystem focus.
Allen Chen is a Principal on the technology investment team at Osage University Partners, focusing on software, hardware, and computing. Before OUP, he spent four years at BMW i Ventures leading early-stage investments in robotics, critical minerals, cybersecurity, and enterprise software, and held operating roles at Uber and Lilium. He started his career as a strategy consultant at L.E.K. Consulting and holds a BBA from Emory University.
Ajay Rayasam joined Osage University Partners in 2021 as an associate on the technology investment team, focusing on software, computing, and hardware opportunities. He previously served as Chief of Staff and Product Manager at enterprise software startup Kubisys, and holds an M.S. from MIT and a B.Sc. from Babson College.
Beth Grafstrom joined OUP in 2015. She previously worked at New Mountain Capital as a Private Equity Fund Accountant and later as the Business Development Company Controller, and before that was a Senior Associate in the Banking Capital Markets Assurance practice at PricewaterhouseCoopers. She holds a B.S. from the University of Scranton and is a New York State CPA.
Britt Kennett joined OUP as an Executive Assistant in 2015. Before that, she spent about ten years at D.A. Kreuter Associates, an executive search firm focused on financial services, where she served as Director of Client Services. She holds a BA in Psychology from Villanova University.
Brittany de Kouchkovsky is Director at Osage University Partners, where she works on startup sourcing and development. She has experience in life sciences venture investment, biotech venture creation, academic technology sourcing, and early-stage therapeutic operations and development.
Claudia Dunnous joined Osage Partners in 2006 and is a CPA with over 25 years of experience across private equity, retail, and manufacturing. She previously served as Vice President of Finance and Operations at Hamburger Color Company, a privately held manufacturer, where she led its sale to a strategic buyer, and earlier provided accounting and business advisory services at Grant Thornton and Laventhol and Horwath. She holds a BA in Economics from Brandeis University and an MBA in Accounting from Drexel University.
Kayti Mangels joined OUP as an Administrative Assistant in 2021. Previously, she supported the Office Manager and COO at Golden Eagle Coin, and before that spent three years as an elementary school teacher in North Philadelphia. She holds a B.S. in Early Childhood Education with a minor in Special Education from Chestnut Hill College.
Kumar Patel joined Osage University Partners in 2019. He previously worked as a Senior Fund Accountant at The Rock Creek Group and as a Supervisor at SEI Investments. He holds a B.A. in Accounting from Arcadia University and is a CPA.
Sami Nabil is an Analyst at Osage University Partners, which he joined after nearly two years as a co-op with the firm. He works across the investment lifecycle, including fund operations, deal sourcing, and diligence. Before OUP, he was an Industrial Engineering Co-op at The Estée Lauder Companies, and he graduated magna cum laude from Drexel University with a B.S. in Physics, where he conducted neutrino physics research; he is also a deferred MBA admit at Columbia Business School.
Justin Robeny joined Osage University Partners in 2024 as an associate on the life sciences team, focusing on biotech investments across therapeutic areas. He previously was an analyst at Octagon Capital Advisors covering oncology and immunology healthcare investments, and worked in clinical operations at Axsome Therapeutics. He holds an M.Sc. in clinical research from the Icahn School of Medicine at Mount Sinai and a B.A. in human health from Emory University.
Author of the OUP insights article on startup equity allocation for academic spinouts.
What they invest in
from 102 of 139 portfolio companiesBiotech ×59Healthtech ×34AI & Machine Learning ×24Medical Devices ×19Deep Tech ×18Hardware ×12Digital Health ×10Enterprise Software ×9
HQs:United States×98Israel×2
Who they back
founder profiles across 78 portfolio companiesFounding team size:solo founder×262 founders×233 founders×124+ founders×17
Where their founders studiedfrom 60 founders with education data
University of California, Berkeley ×13Harvard University ×5Massachusetts Institute of Technology ×5The Johns Hopkins University School of Medicine ×5Stanford University ×4Case Western Reserve University School of Medicine ×2Columbia University ×2Duke University ×2
What their founders studiedfrom 64 founders with field-of-study data
Engineering ×24Life Sciences ×15Computer Science ×14Chemistry ×10Medicine ×7Physics ×7Business & Management ×4Finance & Accounting ×2
Where their founders worked beforefrom 63 founders with career history
Carnegie Mellon University ×3Harvard Medical School ×3Juniper Networks ×3University of Michigan ×3University of Washington ×3Apple ×2Broad Institute of MIT and Harvard ×2Caltech ×2
45 founders hold a PhD · 6 hold an MBA (of 65 with degree data)
Investments · 139 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 32023 · 22022 · 42021 · 12020 · 32019 · 22018 · 32017 · 32016 · 32015 · 345 dated
A Place for Mom is a senior care referral service that helps families find and compare senior living and care options, including assisted living, memory care, independent living, home care, nursing homes, and senior apartments.
ConsumerDigital HealthHealthtechMarketplacesWellness & FitnessVernon Hills, US
Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)
Co-investorsBain Capital Double Impact Fund LPBain Capital Life SciencesBain Capital Tech OpportunitiesBattery VenturesBessemer Venture PartnersBlue Sea Capital+38 more
Ambiq develops ultra-low-power semiconductor solutions and edge AI platforms for IoT and healthcare applications.
AI & Machine LearningIoTSemiconductorsAustin, US
Scott Hanson(Founder)inDennis Sylvester(Founder)inFumihide Esaka(CEO)inScott Goodwin(Executive Officer)inJoseph A. Tautges(Director)Paul Rolls(Executive Officer)
Co-investorsCisco InvestmentsConductive VenturesKleiner PerkinsMatter Venture PartnersMercury FundMichigan Capital Network+5 more
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)+2 more
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in
Co-investorsNextech InvestTorrey Pines Investment
Evolv Technologies provides artificial intelligence-powered screening systems for weapons detection at facilities including schools, hospitals, stadiums, and workplaces, delivered through a subscription model that combines proprietary sensor hardware, cloud-based software, and analytics dashboards with ongoing support services.
Waltham, US
Anil Chitkara(Executive Officer)Michael Ellenbogen(Executive Officer, Director)Kevin O'Brien(Executive Officer)John Kedzierski(Chief Executive Officer, President, and Director)inGeorge C. Kutsor(Chief Financial Officer)Robert Marshall(Chief Revenue Officer)in
Co-investorsDCVC (Data Collective)Lux Capital
Gevo produces low-carbon drop-in fuels and chemicals — including motor fuels, sustainable aviation fuel (SAF), and renewable materials — using CO2 as a renewable carbon source.
CleantechClimate TechEnergyEnglewood, US
Christopher Ryan(Executive Officer)Mike Willis(Executive Officer)Greg Roda(Executive Officer)Patrick Gruber(Executive Officer, Director)inBrett Lund(Executive Officer)Paul D. Bloom(Chief Executive Officer and Director)in
Co-investorsGiant Leap
Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease.
BiotechDigital HealthHealthtechMedical DevicesRedwood City, US
AmirAli Talasaz(Founder)inHelmy Eltoukhy(Founder)inMichael Wiley(Executive Officer)inMichael Bell(Chief Financial Officer)Darya Chudova(Chief Technology Officer)inCraig Eagle(Chief Medical Officer)in
Co-investors8VCAUTHENTIC VENTURESCLI VenturesCota CapitalFelicis VenturesKhosla Ventures+11 more
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalNextech Invest
A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.
BiotechMedia & EntertainmentAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsCorrelation VenturesOrbiMedPfizer VenturesSofinnova Ventures
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+6 more
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Founder)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalSamsara BioCapitalArrive+1 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundSanofi Ventures5AM Ventures+2 more
Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.
BiotechDigital HealthFemTechHealthtechSalt Lake City, US
Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in
BoardMansoor Mirza(Director)
Co-investorsaMoonExcelestar VenturesIntermountain HealthUpStart VenturesVivo CapitalCatalyst Health Ventures+1 more
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSMRL Ventures FundRA CapitalAlphabetAtlas Venture+1 more
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsLongitude CapitalConnecticut InnovationsLifeSci Venture PartnersSR One Capital Managementabrdn plcInvus
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investors5AM VenturesRA CapitalPureTech Health
Eridu develops networking infrastructure optimized for artificial intelligence workloads.
AI & Machine LearningCloud ComputingDeep TechHardwareSaratoga, US
Drew Perkins(Founder)inBrian Kinard(Executive Officer)in
BoardJagdeep Singh(Director)Dipender Saluja(Director)Wen Hsieh(Director)inChristian Gallagher(Director)
Co-investorsBosch VenturesCatapult VenturesMatter Venture PartnersSocratic PartnersTDK VenturesZelda Ventures+13 more
.jpeg){kind=logo}
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersAvoro Capital AdvisorsForesite CapitalSofinnova Ventures
Agita Labs develops hardware security and computer architecture technology focused on secure computation and side-channel resistance techniques.
CybersecurityDeep TechHardwareAnn Arbor, US
Valeria Bertacco(Co-founder)Todd Austin(Co-founder)Amy Wirth(Chief Financial Officer)Lip-Bu Tan(Director)
Algorithmia offers an enterprise AI platform for developing, deploying, and governing machine learning models and AI applications, with tooling tailored to roles across data science, engineering, DevOps, and IT teams.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSeattle, US
Kenneth F. Daniel(Executive Officer, Director)Diego M. Oppenheimer(Executive Officer, Director)inDiego Oppenheimer(Founder)Kenny Daniel(Founder)
BoardTimothy Porter(Director)inAnna Patterson(Director)in
Co-investorsGradient VenturesIn-Q-TelMadrona Venture GroupDeep Fork CapitalNorwest Venture PartnersRakuten Capital+1 more
Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University.
BiotechNew Haven, US
Barbara Fox(Executive Officer, Director)inNicholas J Galli(Executive Officer, Director)Stanley Choy(Executive Officer)inRanjit Bindra(Director)in
BoardColleen Cuffaro(Director)inMatthew Cohen(Director)in
Co-investorsCanaan PartnersConnecticut InnovationsHighCape Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGaingelsGV (Google Ventures)+6 more
__Twitter.png)
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalAgent CapitalBain Capital+3 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM Healthcare InvestmentsHBM PartnersNextech Invest+2 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Alexander Marson(Founder)Kole Roybal(Founder)
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsLuma GroupSoftBank Vision FundWestlake Village BioPartners+4 more
AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.
Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US
William Zell(Executive Officer, Director)William Ruff(Executive Officer)inRobert Lee(Director)inTad Dritz(VP of Development)inJeff Haskett(COO)inBrian Graham(Chief Executive Officer)in
Co-investorsCerity Partners VenturesG2 Venture PartnersHarmonic Growth PartnersJobsOhio VenturesMonte Carlo CapitalTriangle Peak Partners+4 more
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsHBM Healthcare InvestmentsOrbiMed
Brimstone develops co-production processes to manufacture cement, steel, aluminum, and other critical minerals from a single feedstock in an integrated facility.
Advanced ManufacturingCircular EconomyCleantechConstruction TechNew MaterialsOakland, US
Cody Finke(Founder)inHugo Leandri(Founder)in
Co-investorsAccelr8Breakthrough Energy VenturesCollaborative FundCreative Destruction Lab (CDL)DCVC (Data Collective)Fifth Wall+7 more
BiotechLafayette, US
Peter Emtage(Executive Officer)inGreg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)
Co-investorsKleiner PerkinsMission Bay CapitalMission Biocapital
Censys operates an Internet-wide scanning map that provides real-time data on Internet infrastructure, delivered through a platform for exploring exposure, dependencies, and attacker infrastructure.
CybersecurityData & InfrastructureSaaSAnn Arbor, US
J. Alex Halderman(Founder)Zakir Durumeric(Founder)inBrad Brooks(Former CEO)David Corcoran(Founder)Lorne Groe(Former Interim CEO; later CFO/COO)Sarah Ashburn(Chief Revenue Officer)
Co-investorsAscension VenturesDecibel PartnersGreylock PartnersGV (Google Ventures)Hamilton LaneIntel Capital+3 more
nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies.
BiotechLongevityBoston, US
Angelo Lombardo(Founder)David R. Liu(Founder)J. Keith Joung(Founder)Jonathan S. Weissman(Founder)Luigi Naldini(Founder)Luke Gilbert(Founder)
Co-investorsWellington ManagementAtlas VentureCasdin CapitalGV (Google Ventures)Newpath Partners
Clarifai developed AI inference technology and compute orchestration software for running and optimizing machine learning models at scale.
AI & Machine LearningCloud ComputingData & InfrastructureNew York, US
Matthew Zeiler(Founder)in
BoardAlbert Wenger(Director)in
Co-investorsBright Pixel CapitalCorazon CapitalGV (Google Ventures)Lux CapitalMenlo VenturesNew Enterprise Associates (NEA)+10 more
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)inCarol Gallagher(Director)in
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech Invest5AM VenturesClarus VenturesOrbiMed+1 more
Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials.
BiotechDigital HealthHealthtechMorrisville, US
Mark Ubert(Executive Officer)Jesse Watson(Director)Brian Carney(Director)Jeff L. Williams(Executive Officer, Director)Melissa Daniels(Director)Christopher K. Porter(Executive Officer)
Co-investorsCreathor VenturesHatteras Venture Partners
Corelight provides network detection and response (NDR) software that uses agentic triage to automatically consolidate security alerts into entity-centric cases with evidence-backed investigation summaries.
AI & Machine LearningCybersecurityEnterprise Software
Seth Hall(Founder)inGregory Bell(Chief Strategy Officer & Co-Founder)inBrian Dye(CEO)inGreg Bell (CEO)(Founder)Robin Sommer(Founder)Vern Paxson(Founder)
Co-investorsAccelCisco InvestmentsDelta-v CapitalEnergy Impact PartnersFlucas VenturesGaingels+7 more
Crozet, US
Randy Caldejon(Chairman, Chief Executive Officer and President)Erik Breuhaus(Chief Financial Officer)Peter Shaw(Vice President)in
BoardMatthew Swartz(Director)
Co-investorsTFX CapitalTiburon
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesShah Family OfficeAlly Bridge GroupDe Novo VenturesJanus Henderson Investors+3 more
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation Fund+7 more
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardJonathan Leff(Director)Robert Jackson(Director)
Co-investorsBiotech Investments S.R.Oi&i Biotech FundDeerfield Management CompanySofinnova Ventures
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalPfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+12 more
Elementary builds data observability tools that monitor data quality and reliability for modern data teams.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareTel Aviv-Yafo, IL
Maayan Salom(Founder)inOr Avidov(Founder)in
Co-investorsCowboy VenturesICON - Israel Collaboration NetworkModern TechnicalY CombinatorAccuro TrusteesTetration Labs+2 more
Elementary Robotics develops machine vision inspection systems for industrial quality control and defect detection.
Advanced ManufacturingAI & Machine LearningRobotics
Arye Barnehama(Founder)in
Co-investorsIdealabRiot VenturesThundermark CapitalFathom CapitalFika VenturesRewired+4 more
EnaChip develops integrated magnetic structures — thin, small inductors fabricated with semiconductor-compatible electroplating — for point-of-load power delivery in AI infrastructure, advanced packaging, chiplets, and edge systems.
Deep TechHardwareSemiconductorsWilmington, US
Trifon M Liakopoulos(Executive Officer, Director, Promoter)Mark Allen(Co-Founder & CTO)Mark Popovich(CEO)inMichael Cassidy(Director)Michael Poisel(Director)
BoardMICHAEL BURYCHKA(Director)in
Co-investorsAnzu PartnersBoston Seed Capital
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)Sanofi VenturesThe Column GroupAbingworth+2 more
Everactive develops ultra-low power, self-powered systems-on-chip (SoCs) for Ambient IoT devices that sense, process, and wirelessly transmit data using harvested environmental energy instead of batteries.
HardwareIoTSemiconductorsSan Jose, US
Benton Calhoun(CEO and Co-Founder)inDavid Wentzloff(CTO and Co-Founder)inBrendan R Richardson(Executive Officer, Director)
BoardGeorge Kastendike(Director)Greg Papadopoulos(Director)inJack Busch(Director)
Co-investorsAsahi Kasei Corporate Venture CapitalBlue Bear Capital PartnersIn-Q-TelNew Enterprise Associates (NEA)ABB Technology VenturesFluke Venture Partners+1 more
Zhiming Shen(Founder)in
Co-investorsCambium CapitalCandou VenturesCelesta CapitalEastlink Capital PartnersGaingelsLaunch NY+2 more
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)inSteven Gillis(Executive Officer, Director, Promoter)in
Co-investorsARCH Venture PartnersPolaris Partners
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.
BiotechHealthtechMedical DevicesSan Diego, US
Marc Nasoff(Chief Scientific Officer)
BoardJay B. Lichter(Ph.D.)in
Co-investorsVivo CapitalLilly Asia VenturesAvalon BioVentures
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesGaingelsHarpoon Ventures+10 more
Hack The Box provides hands-on training and simulation platforms for cybersecurity blue teams, including labs, courses, and incident response exercises designed to develop skills in SOC operations, digital forensics, and threat hunting.
AI & Machine LearningCybersecurityDeveloper ToolsEdTechEnterprise Software
Co-investorsBrighteye VenturesMarathon Venture CapitalPaladin Capital Group
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersAlexandriaDeerfield Management CompanyFidelity InvestmentsHBM Healthcare Investments+5 more
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.
HealthtechMedical DevicesLexington, US
Carl Vause(Chief Executive Officer and President)inMira Sahney(Executive Officer, Director)inDavid Myung(Director)
BoardMichael Hawkins(Director)Wende Hutton(Director)inWilliam Harrington(Director)in
Co-investorsCanaan PartnersTreo Ventures, LlcJohnson & Johnson Innovation – JJDC
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersSanderling VenturesSanofi VenturesSPRINGROCK VENTURES+4 more
Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.
BiotechDigital HealthChapel Hill, US
Jenny Ting(Director and Co-founder)Matthew Cohen(Director)Lev Osherovich(Director)Mark Vellaca(Director)Anil Goyal(CEO and Director)
BoardBenjamin Scruggs(Director)
Co-investorsDelin VenturesHatteras Venture Partners
IgniteTech is an AI-first enterprise software company that acquires, revitalizes, and supports a portfolio of mission-critical software products for organizations worldwide.
AI & Machine LearningEnterprise SoftwareSaaS
Eric Vaughan(CEO)
Infinite Uptime builds PlantOS, a prescriptive AI platform for heavy manufacturing that reads mechanical and process-induced fault signatures to tell plant operators which equipment fault to fix, why, and by when.
Advanced ManufacturingAI & Machine LearningIoTMenlo Park, US
Raunak Bhinge(Founder & MD)inJean-David Margulici(Executive Officer, Director)Yung Chih Chen(Founder)Karthikeyan Natarajan(Chief Executive Officer)
Co-investorsAvataar Venture PartnersDorm RoomGiTV, Inc.Mayfield FundPear VCTDK Ventures+3 more
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundPfizer Venture InvestmentsQuan CapitalBain Capital Life Sciences+3 more
A patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases.
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsWestlake Village BioPartnersKleiner PerkinsVersant Ventures
Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.
Co-investorsMindset VenturePolaris Partners
Kymeta develops flat-panel satellite antennas and connectivity terminals, including its u5 and u8 product lines, that switch between LEO and GEO networks for mobile land and maritime use.
Defense TechHardwareSpace TechRedmond, US
Marc Stolzman(Executive Officer)inBill Marks(Executive Officer)Keith Cochran(Executive Officer)inManny Mora(CEO)inAnne(Chief Financial Officer)inRyan(Chief Scientist)in
Co-investorsLux CapitalManta Ray VenturesTectonic VenturesIntellectual Ventures
American network security company offering malware sandboxing and AI-based network detection and response; acquired by VMware in 2020.
Redwood City, US
Giovanni Vigna(Executive Officer, Director)Engin Kirda(Executive Officer)Christopher Kruegel(Executive Officer)Jens Andreassen(Executive Officer, Director)
BoardJohn Walecka(Director)inAndreas Von Blottnitz(Director)
Co-investorsPresidio VenturesRedpoint VenturesBallistic VenturesHeadlineNTT FinanceThomvest Ventures
Global leader in silicon photonics, first to achieve direct 'fiber to the chip' integration on CMOS.
Carlsbad, US
Eli Yablonovitch(Director)Greg Young(Executive Officer, Director)inTom Foody(Executive Officer)Axel Scherer(Founder)
BoardAndy Rappaport(Director)Rohini Chakravarthy(Director)in
Co-investorsATEL VenturesAugust CapitalCisco InvestmentsTEL Venture Capital, Inc.New Enterprise Associates (NEA)
MC10 developed conformal BioStamp wearable sensors and clinical analytics for physiological data capture in clinical research.
BiotechDigital HealthHealthtechMedical DevicesLexington, US
John Rogers(Director)David Icke(Executive Officer, Director)Alice Sansone(Executive Officer)Steven N. Tannenbaum(Executive Officer)Scott D. Pomerantz(Executive Officer, Director)
BoardMarc Singer(Director)in
Co-investorsBraemar Energy VenturesMitsui Global InvestmentWindham Capital PartnersAberdare VenturesNorth Bridge Venture Partners & Growth Equity
Menlo Security provides a browser security platform that protects both human users and AI agents through a hybrid architecture combining local security controls with cloud-based threat protection.
AI & Machine LearningCybersecurityEnterprise SoftwareMountain View, US
Amir Ben-Efraim(Founder)inPoornima DeBolle(Founder)in
Co-investorsBaruch Future VenturesEngineering CapitalGeneral CatalystJuniperoVista Equity PartnersWillowTree Ventures+3 more
.png)
Metalenz develops metasurface optics technology for optical sensing in consumer and industrial devices.
Deep TechHardwareSemiconductorsStoneham, US
Federico Capasso(Co-founder)inRob Devlin(Co-Founder and CEO)in
BoardXuhui Shao(Director)in
Co-investorsBantam GroupBraemar Energy VenturesFoothill VenturesGlobal BrainIntel CapitalM Ventures+5 more
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved vagus nerve stimulation treatment for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.
HealthtechMedical Devices
Jordan Curnes(Co-Founder)in
Co-investorsGreen Park & Golf VenturesLongitude CapitalUS Venture Partners
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Co-investorsCanaan PartnersF-Prime CapitalLumira VenturesMission BiocapitalMonograph Capital Partners
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+6 more
Opsys develops solid-state scanning LiDAR sensors with no moving parts, using VCSEL and SPAD chip technology for autonomous driving and industrial applications.
AI & Machine LearningDeep TechHardwareRoboticsIsrael, IL
Guy Gertel(Founder)Rafi Harel(Founder)
Co-investors83NorthSaban VenturesTransLink Capital
Overland AI develops ground autonomy solutions for military vehicles and land operations, enabling autonomous mobility without human operators.
AI & Machine LearningDefense TechRoboticsSeattle, US
Byron Boots(Founder)inStephanie Bonk(Founder)inGreg Okopal(Founder)inJonathan Fink(Executive Officer)
BoardChristopher Morales(Director)
Co-investors8VCAlumni VenturesAscend Venture CapitalCubit CapitalOvermatchPioneer Square Labs+7 more
Picwell operates ALEX, a benefits decision-support platform that combines plan recommendations, enrollment, benefits administration, and year-round guidance for employees.
HR TechInsurTechSaaSPhiladelphia, US
Thomas Baker(Executive Officer, Director)Jonathan Thompson Kolstad(Executive Officer, Director)Robert James Town(Executive Officer, Director)Jay Silverstein(Executive Officer, Director)inAnirudh Vemprala(Executive Officer, Director)
BoardKevin Hill(Director)
Co-investorsBlue Venture FundsMassMutual VenturesSeaX VenturesBlueCross BlueShield Venture Partners
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)Sofinnova VenturesOrbiMedSofinnova Venture Partners
PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations.
BiotechHealthtechLongevityCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Co-Founder & Member, Scientific Advisory Board)David H. Mack(Co-Founder, President & CEO)Thomas Shenk(Co-Founder)Deepika Jalota(Chief Development Officer)
Co-investorsAvoro Capital AdvisorsNextech InvestRA CapitalViking GlobalWellington ManagementOrbiMed
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investors5AM VenturesIllumina VenturesAlexandriaLilly Asia VenturesS28 CapitalUPMC Enterprises
Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.
Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US
Rob Schoelkopf(Sterling Professor, Founder)inLuigi Frunzio(Founder)Ray SmetsinMichel Devoret(Founder)Robert Schoelkopf(Founder)
Co-investorsARCH Venture PartnersCanaan PartnersConnecticut InnovationsF-Prime CapitalFitz Gate VenturesIn-Q-Tel+2 more
Quintessent develops optical connectivity solutions to address chip-to-chip communication bottlenecks in large-scale computing and AI systems.
AI & Machine LearningCloud ComputingDeep TechHardwareSemiconductorsSanta Barbara, US
Alan Liu(CEO, Co-Founder & Board Member)inBrian Koch(VP of Engineering & Co-Founder)inJohn Bowers(Chairman of the Board & Co-Founder)
Co-investorsEntrada VenturesFoothill VenturesM VenturesSierra Ventures
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in
Co-investorsARCH Venture PartnersRidgeback CapitalVenrockLilly Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedPfizer Venture Investments+6 more
Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.
AI & Machine LearningBiotechBoston, US
George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in
Co-investorsAstellas Venture Management LLCSofinnova Partners
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalPeregrine VenturesAbbVieDeerfield Management CompanyJJDCNovartis Venture Fund+3 more
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
BoardGeoffrey von Maltzahn(Director)in
Co-investorsAmerican Family VenturesARCH Venture PartnersCatalytic Impact FoundationF-Prime CapitalFlagship PioneeringGV (Google Ventures)+8 more
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsVivo CapitalWellington ManagementLumira VenturesRA CapitalRed Tree VentureSBI Investment
Seismos provides an AI intelligence layer that converts acoustic signals and sensor measurements into real-time completion decisions for oil and gas well operators.
AI & Machine LearningDeep TechEnergyAustin, US
Panagiotis Adamopoulos(Executive Officer, Director)Panos Adamopoulos(Founder)inJeffrey Harris(Director)John Bain(Director)
BoardNoah Doyle(Director)in
Co-investorsEdison PartnersJavelin Venture Partners
SiFive develops processor IP based on the open-standard RISC-V instruction set architecture, offering customizable and scalable chip designs.
Deep TechHardwareSemiconductorsSan Francisco, US
Yunsup Lee(Co-Founder & Chief Technology Officer)inKrste Asanovic(Co-Founder & Chief Architect)inAndrew Waterman(Co-Founder & Chief Engineer)inStefan A Dyckerhoff(Executive Officer, Director)inNaveed Sherwani(Executive Officer)inPatrick Little(Chairman, President & CEO)in
Co-investorsBerkeley SkyDeck FundCoatue ManagementIbex InvestorsIntel CapitalProsperity7 VenturesQualcomm Ventures+9 more
The site is a Dutch-language affiliate portal that ranks and reviews online casinos targeting players in the Netherlands, offering casino comparisons, bonus guides, and gambling information.
ConsumerMedia & Entertainment
Co-investorsJavelin Venture PartnersUS Venture Partners
Snowcap Compute develops superconducting computing platforms using Josephson Junctions to replace semiconductor transistors, delivering orders-of-magnitude greater energy efficiency for AI and high-performance computing workloads.
AI & Machine LearningDeep TechSemiconductorsSan Francisco, US
Anna Herr(Founder)inQuentin Herr(Founder)inMichael Shamus Lafferty(Executive Officer, Director)Michael Lafferty(Founder)
BoardPat Gelsinger(Director)inRichard Hyman(Director)
Co-investorsPlayground GlobalATEL VenturesCambium CapitalPage One Ventures
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more
StreetLight provides big data analytics for transportation planning and infrastructure investment decisions.
Climate TechData & InfrastructureGovTechLogistics & Supply ChainMobility & TransportationSan Francisco, US
Paul Friedman(Founder, Chief Technology Officer)inLaura Schewel(Executive Officer, Director, Promoter)in
BoardBill Perry(Director)Scott Pinizzotto(Director)Marc Singer(Director)inDarlene Mann(Director)
Co-investorsACTIVATE CAPITAL PARTNERSWestern Technology Investment
Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.
AI & Machine LearningEnterprise SoftwareSaaS
Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)inAnirudh Sriram(Chief Technology Officer)inPrakash Gupta(Chief Revenue Officer)in
Co-investorsAndreessen HorowitzClear VenturesFoundation CapitalMyriad Venture Partners
Trellis Air develops technology aimed at drying air using less energy.
CleantechClimate TechEnergySomerville, US
Russ Wilcox(Executive Officer, Director)
BoardCraig Shapiro(Director)
Co-investorsWorkshop Venture PartnersFounder Collective
Trulite Health builds Truity, a health optimization platform that delivers clinical, social, and behavioral decision support and patient-facing nudges to providers and care teams at the point of care.
Digital HealthHealthtechSaaSTempe, US
Alan C. Roga(Executive Officer, Director)inJohn Barravecchia(Executive Officer)inShaung Liu(Executive Officer)in
BoardCaleb DesRosiers(Director)
Co-investorsOsage Venture PartnersService Provider CapitalInflect Health
.png)
Arcadia (urjanet.com) offers a platform that unifies utility bill and interval data, tariff and energy rate calculations, and solar and storage analysis into energy data and analytics.
CleantechClimate TechData & InfrastructureEnergyAtlanta, US
SANJOY MALIK(Executive Officer, Director)in
BoardPETER KIGHT(Director)inSTEVE FREDRICK(Director)inSIG MOSLEY(Director)DAVID RATCLIFFE(Director)
Co-investorsCorrelation VenturesGrotech VenturesOak HC/FTCommerce VenturesGRA VentureImlay Investments
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)
Co-investorsAvoro Capital AdvisorsOrbiMedPontifax Venture CapitalCasdin CapitalOmega Funds
Verdox develops an electrochemical carbon capture system that uses electrical energy alone to capture and release CO₂ from both industrial point sources and ambient air.
CleantechClimate TechDeep Tech
Alan Hatton(Founder)Brian Baynes(Founder)Sahag Voskian(Founder)
Co-investorsAzolla VenturesBreakthrough Energy VenturesLowercarbon CapitalPrime Impact Fund
Verve Motion develops the SafeLift exosuit, a wearable device designed to reduce workplace injuries and increase productivity for physically demanding jobs.
Future of WorkHardwareLogistics & Supply ChainRoboticsCambridge, US
Ignacio Galiana(Founder)in
Co-investors515 VenturesConstruct CapitalCybernetix VenturesFounder CollectivePillar VCSafar Partners
Virtue AI offers an enterprise AI security platform that applies real-time guardrails, red-teaming, and compliance controls to AI models and agentic systems.
AI & Machine LearningCybersecurityEnterprise SoftwareSan Francisco, US
Sanmi Koyejo(Founder)inBo Li(Founder)inDawn Song(Founder)inCarlos Guestrin(Founder)in
Co-investorsLightspeed Venture PartnersWalden Catalyst
Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.
Somerville, US
Jennifer A. Lewis(Executive Officer, Director)
BoardJiong Ma(Director)Clinton Bybee(Director)in
Co-investorsBraemar Energy VenturesIn-Q-TelARCH Venture Partners
Xscape Photonics develops laser light sources for AI infrastructure, including comb-based laser modules and wafer-scale integrated multicolor laser chiplets.
AI & Machine LearningDeep TechHardwareSemiconductorsFort Lee, US
Alexander Gaeta(Executive Officer, Director)inVivek Raghunathan(Co-Founder & CEO)inYoshitomo Okawachi(Executive Officer)Alexander Kash(Executive Officer, Director)Alex(Co-Founder & President)Yoshi(Co-Founder & VP of R&D)
Co-investorsCisco InvestmentsFathom FundIAG Capital PartnersLifeX VenturesNVIDIAAddition+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aerovate TherapeuticsAGTCArtizan BiosciencesAtsena TherapeuticsAvid RadiopharmaceuticalsBioAgeBlade TherapeuticsBody LabsCapella BioscienceCardioxyl PharmaceuticalsCartesiaCleave TherapeuticsCoho TherapeuticsDICE TherapeuticsE-scape BioEinblickEmbodiedGraphite Bio, Inc.HiddenWeightsIconic TherapeuticsIonQKolltan PharmaceuticalsLandos BiopharmaLunaDNAMediSix TherapeuticsMillendo TherapeuticsModis TherapeuticsNeurosNidobioNuMatOtonomyPalladio BiosciencesParacosmPerceptive AutomataResolv TechnologySelecta BiosciencesSynthorxTangent Medical TechnologiesVector Space Systems
Exits · 30
17 IPOs · 13 acquisitions · showing 21A Place for MomNASDAQ: GDRXAmbiqNYSE: AMBQBeam TherapeuticsNASDAQ: BEAMContext TherapeuticsNASDAQ: CNTXEvolv TechnologiesNASDAQ: EVLVGevoNASDAQ: GEVOGuardant HealthNASDAQ: GHKura OncologyNASDAQ: KURAMirna TherapeuticsOTC: SYBXPrecision BioSciencesNASDAQ: DTILPrime MedicineNASDAQ: PRMEQ32 BioNASDAQ: QTTBSera PrognosticsNASDAQ: SERASpero TherapeuticsNASDAQ: SPROVeradermicsNYSE: MANEVor BiopharmaNASDAQ: VORAerovate Therapeuticsacq. by Jade BiosciencesMC10acq. by MedidataMillendo Therapeuticsacq. by Tempest TherapeuticsModis Therapeuticsacq. by ZogenixSynthorxacq. by Sanofi
Portfolio news
latest coverage across their companies
Veradermics · biospace.com · Sep 4, 2026
Prime Medicine · biospace.com · Sep 3, 2026
KenSci · chiefhealthcareexecutive.com · Aug 17, 2026
Sera Prognostics · stocktitan.net · Aug 12, 2026
Vor Biopharma · stocktitan.net · Aug 6, 2026
Censys · PR Newswire · Jul 22, 2026
Frequently asked questions
- How many investments has OUP (Osage University Partners) made?
- OUP (Osage University Partners) has 139 tracked investments, 30 of which have exited, including 3 dated in the last 24 months.
- What stage does OUP (Osage University Partners) invest at?
- OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is OUP (Osage University Partners)'s typical check size?
- OUP (Osage University Partners) typically writes checks of $1M – $20M.
- What sectors does OUP (Osage University Partners) focus on?
- OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.
- Where is OUP (Osage University Partners) located?
- OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.
- Does OUP (Osage University Partners) lead rounds?
- Yes, OUP (Osage University Partners) leads investment rounds.
- Who does OUP (Osage University Partners) co-invest with?
- OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, GV (Google Ventures), Canaan Partners, among 333 tracked co-investors.
Media · Podcasts & interviews
featuring the teamUniversity Spinouts and Deep Tech Investing | Marc Singer | Osage University Partners (OUP)
Deep Tech Leaders · Marc Singer
Ventures #15 w/ Matt Cohen - Managing Partner @ Osage University Partners (OUP) | BIOS
BIOS · Matt Cohen
Founder's Equity: Formation, Dilution, Industry Averages - Manny Stockman, Osage University Partners
UCLA TDG · Manny Stockman
Marc Singer, John Lee (Osage University Partners)
Marc Singer · vimeo.com
Advisory Boards in Academic Innovation: Three University Models
Osage University Partners
SBIR/STTR Reauthorization: Tips and Tricks for Navigating New Funding Opportunities
Osage University Partners
Images
Co-investors · 47
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
Deerfield Management Company is a healthcare-focused investment firm, founded in 1994, that advances healthcare through investment, intelligence, and philanthropy.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
▶35 more co-investors
Versant VenturesHatteras Venture PartnersBraemar Energy VenturesGeneral CatalystKhosla VenturesJavelin Venture PartnersBreakthrough Energy VenturesDeep Fork CapitalDomain AssociatesOmega FundsRiverVest Venture PartnersAPERTURE Venture PartnersPlug and Play VenturesMadrona Venture GroupSierra VenturesAmerican Express Ventures (Amex)G2 Venture PartnersEQT Life SciencesMassMutual VenturesJAZZ Venture PartnersEngineering CapitalSR One Capital ManagementJohnson & Johnson Innovation – JJDCAberdare VenturesSignet Healthcare PartnersCompany CapitalGutbrain VenturesCalibrate VenturesVenture Guides Management, L.P.Pivotal Life SciencesNewfund CapitalAmara VCMedical Excellence CapitalChrysalixBrightCap Investment Advisor AD
Firms observed investing alongside OUP (Osage University Partners), from public investor directories. Shared companies are the overlap with OUP (Osage University Partners)'s recorded portfolio.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Robert Bosch Venture Capital GmbH (Bosch Ventures) is the corporate venture capital arm of Robert Bosch, headquartered in Stuttgart, Germany, with offices across Europe, the US, Israel, and China.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
Lauder Partners is the venture investment vehicle of Gary Lauder, investing in early- and growth-stage private companies across a broad range of technology, healthcare, energy and consumer sectors.